Free Newsletter
Sinovac cuts full-year revenue forecast
Sinovac Biotech shares fell 10 percent Monday, a day after the vaccine manufacturer cut its full-year revenue forecast for the second time, citing continued weakness in Chinese demand for vaccines. "The vaccine market in China is experiencing a much longer than originally expected demand weakness in the market following the unfounded media reports about vaccine safety in China's Shanxi province," the company says in a release. Sinovac release | Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
More Research Reports >>
SHARE
WITH: